A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Benjamin K TomlinsonJoseph M TuscanoMehrdad AbediJeanna WelbornMili AroraRobert T O'DonnellTed WunBrian A JonasPublished in: American journal of hematology (2019)